<DOC>
	<DOCNO>NCT01535456</DOCNO>
	<brief_summary>The main purpose study see tracer use determine well chemotherapy work patient certain type leukemia .</brief_summary>
	<brief_title>FLT-PET Imaging MDS</brief_title>
	<detailed_description>Primary objective 1 . To evaluate FLT-PET uptake show variation treatment course subject MDS treat 5-azacitidine therapy Secondary objectives 2 . To assess FLT-PET uptake heterogeneity within give subject treat 5-azacitidine therapy 3 . To generate preliminary data regard correlation FLT-PET imaging parameter clinical response base bone marrow aspirate/biopsy</detailed_description>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>All subject previously untreated , Intermediate2 High risk myelodysplastic syndrome eligible . These patient international prognostic scoring system ( IPSS ) score 1.5 3.5 base bone marrow blast percentage , karyotype , number cytopenias 26 . Subjects receive standard FDAapproved dose schedule 5azacitidine . This dose 75mg/m2 SQ IV daily seven day cycle repeat every 28 day The subject 's treating physician must initial intent treat least four cycle therapy Subjects must ECOG performance status 0 , 1 , 2 Subjects must treat chemotherapy radiation another malignancy within precede 6 month Subjects must &gt; 18 year age Subjects must serum creatinine &lt; 2.0 mg/dL and/or calculate GHF 50 ml/min/1.73m ( MRDR formula ) great Subjects must serum direct bilirubin &lt; 2.0 mg/dL unless related Gilbert 's syndrome hemolysis . Alkaline phosphatase , SGOT ( AST ) , SGPT ( ALT ) must less 4 x upper limit normal Women must pregnant breastfeed Women childbearing potential sexually active male strongly advise use accept effective method contraception Subjects pregnant breast feeding Subjects therapy 5azacitidine recommend first line treatment . Allogeneic stem cell transplantation patient suitable donor , lack comorbidities , good performance status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>5 azacitidine</keyword>
	<keyword>FLT PET</keyword>
</DOC>